{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:49:51Z","timestamp":1793836191507,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to evaluate the adverse events (AEs) associated with burosumab in real-world clinical practice using data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), and to provide evidence for optimizing its clinical safety management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data for this study were retrieved from the FAERS database via OpenVigil 2.1, covering the period from the first quarter of 2018 to the third quarter of 2024. Disproportionality analyses were performed to quantify adverse event signals associated with burosumab, employing four established methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-Item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5054 adverse events (AEs) associated with burosumab were identified. Commonly reported AEs included injection site reactions, musculoskeletal pain, restless leg syndrome, skeletal deformities, and corrective orthopedic surgeries necessitated by severe bone deformities. Additionally, several concerning AEs were observed, such as hyperparathyroidism, tertiary hyperparathyroidism, nephrocalcinosis, and dental and periodontal complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides an initial evaluation of burosumab\u2019s safety in real-world practice, identifying noteworthy adverse event signals that broaden current understanding and support more informed prescribing decisions for patients with XLH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04267-9","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:28:41Z","timestamp":1772245721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system"],"prefix":"10.1186","volume":"21","author":[{"given":"Tingting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"7","key":"4267_CR1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM. Insogna KL: a clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381\u201388.","journal-title":"J Bone Miner Res"},{"key":"4267_CR2","doi-asserted-by":"crossref","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig. 2014;124(4):1587\u201397.","DOI":"10.1172\/JCI72829"},{"key":"4267_CR3","doi-asserted-by":"publisher","first-page":"1414509","DOI":"10.3389\/fendo.2024.1414509","volume":"15","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang R, Chen Z, Bai Y, He Q. Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia. Front Endocrinol. 2024;15:1414509.","journal-title":"Front Endocrinol"},{"issue":"6","key":"4267_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN. Burosumab: first global approval. Drugs. 2018;78(6):707\u201314.","journal-title":"Drugs"},{"issue":"12","key":"4267_CR5","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/jbmr.4318","volume":"36","author":"IR Hartley","year":"2021","unstructured":"Hartley IR, Collins MT. Burosumab for tumor-Induced osteomalacia: not enough of a good thing. J Bone Miner Res. 2021;36(12):2453\u201354.","journal-title":"J Bone Miner Res"},{"key":"4267_CR6","doi-asserted-by":"crossref","unstructured":"Ward LM, H\u00f6gler W, Glorieux FH, Portale AA, Whyte MP, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, et al. Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus. 2024;8(1):ziad001.","DOI":"10.1093\/jbmrpl\/ziad001"},{"key":"4267_CR7","doi-asserted-by":"crossref","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet (London, England). 2019;393(10189):2416\u201327.","DOI":"10.1016\/S0140-6736(19)30654-3"},{"key":"4267_CR8","doi-asserted-by":"crossref","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA. Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):189\u201399.","DOI":"10.1016\/S2213-8587(18)30338-3"},{"issue":"21","key":"4267_CR9","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, Padidela R, Van't Hoff W, Mao M, Chen CY, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987\u201398.","journal-title":"N Engl J Med"},{"key":"4267_CR10","doi-asserted-by":"crossref","unstructured":"Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R, Kolta S, Lachmann RH, Lecoq AL, Ralston SH, et al. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open. 2023;9(1).","DOI":"10.1136\/rmdopen-2022-002676"},{"issue":"2","key":"4267_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, Bell C, Bright-Ponte SJ, Botsis T, Bouri K, et al. Use of data mining at the Food and Drug Administration. J Am Med Inf Assoc. 2016;23(2):428\u201334.","journal-title":"J Am Med Inf Assoc"},{"issue":"6","key":"4267_CR12","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, H\u00f6cker J. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One. 2016;11(6):e0157753.","journal-title":"PLoS One"},{"issue":"1","key":"4267_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"4267_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u201386.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"4267_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG. O\u2019Neill RT: use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf"},{"issue":"4","key":"4267_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"4267_CR17","doi-asserted-by":"publisher","first-page":"688309","DOI":"10.3389\/fendo.2021.688309","volume":"12","author":"GI Baroncelli","year":"2021","unstructured":"Baroncelli GI, Mora S. X-Linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management. Front Endocrinol. 2021;12:688309.","journal-title":"Front Endocrinol"},{"issue":"9","key":"4267_CR18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/jbmr.4641","volume":"37","author":"N Fratzl-Zelman","year":"2022","unstructured":"Fratzl-Zelman N, Hartmann MA, Gamsjaeger S, Rokidi S, Paschalis EP, Blouin S, Zwerina J. Bone matrix mineralization and response to burosumab in adult patients with X-linked hypophosphatemia: results from the phase 3, single-arm International trial. J Bone Miner Res. 2022;37(9):1665\u201378.","journal-title":"J Bone Miner Res"},{"key":"4267_CR19","doi-asserted-by":"crossref","unstructured":"Ali DS, Mirza RD, Alsarraf F, Hussein S, Abu Alrob H, Appelman-Dijkstra NM, Beck-Nielsen SS, Biosse-Duplan M, Brandi ML, Carpenter, et al. Systematic review: efficacy of medical therapy on outcomes important to adult patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2024.","DOI":"10.1210\/clinem\/dgae890"},{"key":"4267_CR20","doi-asserted-by":"crossref","unstructured":"Lecoq AL, Chaumet-Riffaud P, Blanchard A, Dupeux M, Rothenbuhler A, Lambert B,Durand E, Boros E, Briot K, Silve C, et al. Hyperparathyroidism in patients with X-linked hypophosphatemia. J Bone Miner Res. 2020;35(7):1263\u201373.","DOI":"10.1002\/jbmr.3992"},{"key":"4267_CR21","doi-asserted-by":"crossref","unstructured":"DeLacey S, Liu Z, Broyles A, El-Azab SA, Guandique CF, James BC, Imel EA. Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone. 2019;127:386\u201392.","DOI":"10.1016\/j.bone.2019.06.025"},{"key":"4267_CR22","doi-asserted-by":"crossref","unstructured":"Zhukouskaya V, Ertl A, Berkenou J, Audrain C, Bardet C, Chaussain C, Rothenbuhler A, Linglart A. Hyperparathyroidism after 3 years of burosumab in children affected with X-linked hypophosphatemia. Ann Endocrinol. 2023;84(5):544.","DOI":"10.1016\/j.ando.2023.07.108"},{"key":"4267_CR23","doi-asserted-by":"publisher","first-page":"117324","DOI":"10.1016\/j.bone.2024.117324","volume":"190","author":"R Padidela","year":"2025","unstructured":"Padidela R, Rayner L, Boot AM. Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during burosumab treatment. Bone. 2025;190:117324.","journal-title":"Bone"},{"issue":"7","key":"4267_CR24","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/ndt\/gfp115","volume":"24","author":"BA Vervaet","year":"2009","unstructured":"Vervaet BA, Verhulst A, D\u2019Haese PC, De Broe ME. Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transplant. 2009;24(7):2030\u201335.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"4267_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00467-013-2466-z","volume":"29","author":"MG Penido","year":"2014","unstructured":"Penido MG, Alon US. Hypophosphatemic rickets due to perturbations in renal tubular function. Pediatr Nephrol. 2014;29(3):361\u201373.","journal-title":"Pediatr Nephrol"},{"key":"4267_CR26","doi-asserted-by":"crossref","unstructured":"Portale AA, Ward L, Dahir K, Florenzano P, Ing SW, Jan de Beur SM, Martin RM, Meza-Martinez AI, Paloian N, Ashraf A, et al. Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. J Bone Miner Res. 2024;39(10):1493\u2013502.","DOI":"10.1093\/jbmr\/zjae127"},{"issue":"11","key":"4267_CR27","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","volume":"37","author":"NJ Paloian","year":"2022","unstructured":"Paloian NJ, Nemeth B, Sharafinski M, Modaff P, Steiner RD. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2022;37(11):2667\u201377.","journal-title":"Pediatr Nephrol"},{"key":"4267_CR28","doi-asserted-by":"crossref","unstructured":"Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab. 2015;100(7):2565\u201373.","DOI":"10.1210\/jc.2015-1551"},{"key":"4267_CR29","doi-asserted-by":"crossref","unstructured":"Levi S, Landau D, Davidovits M, Shapira Rootman M, Brener A, Gal S, Borovitz Y, Goldberg O, Bello R, Cleper R, et al. Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study. Front Pediatr. 2024;12:1487890.","DOI":"10.3389\/fped.2024.1487890"},{"key":"4267_CR30","doi-asserted-by":"crossref","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, H\u00f6gler W, Boot AM, Padidela R, Van't Hoff W, Gottesman GS, Chen A, et al. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2022;107(3):813\u201324.","DOI":"10.1210\/clinem\/dgab729"},{"key":"4267_CR31","doi-asserted-by":"publisher","first-page":"1430921","DOI":"10.3389\/fped.2024.1430921","volume":"12","author":"NJ Paloian","year":"2024","unstructured":"Paloian NJ, Boyke-Lohmann LR, Steiner RD. X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab. Front Pediatr. 2024;12:1430921.","journal-title":"Front Pediatr"},{"issue":"10","key":"4267_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1590\/S1807-59322010001000017","volume":"65","author":"MA Souza","year":"2010","unstructured":"Souza MA, Soares Junior LA, Santos MA, Vaisbich MH. Dental abnormalities and oral health in patients with hypophosphatemic rickets. Clinics (Sao Paulo, Brazil). 2010;65(10):1023\u201326.","journal-title":"Clinics (Sao Paulo, Brazil)"},{"key":"4267_CR33","doi-asserted-by":"crossref","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383\u201393.","DOI":"10.1002\/jbmr.3475"},{"key":"4267_CR34","doi-asserted-by":"crossref","unstructured":"Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, H\u00f6gler W, Simmons JH, Gottesman GS, Padidela R, Namba N, et al. Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2022;107(8):e3241\u201353.","DOI":"10.1210\/clinem\/dgac296"},{"key":"4267_CR35","doi-asserted-by":"crossref","unstructured":"Herv\u00e9 A, Gadion M, Herrou J, Izart M, Linglart A, Cohen-Solal M, Lecoq AL, Kamenicky P, Briot K, Chaussain C, et al. Improved oral health in adults with X-linked hypophosphatemia treated with burosumab. J Clin Endocrinol Metab. 2024.","DOI":"10.1210\/clinem\/dgae398"},{"issue":"1","key":"4267_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41368-023-00259-8","volume":"15","author":"EJ Lira Dos Santos","year":"2023","unstructured":"Lira Dos Santos EJ, Nakajima K, Po J, Hanai A, Zhukouskaya V, Biosse Duplan M, Linglart A, Shimada T, Chaussain C, Bardet C. Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia. Int J Oral Sci. 2023;15(1):53.","journal-title":"Int J Oral Sci"},{"issue":"4","key":"4267_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4267_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.gaitpost.2020.07.007","volume":"81","author":"GT Mindler","year":"2020","unstructured":"Mindler GT, Kranzl A, Stauffer A, Haeusler G, Ganger R, Raimann A. Disease-specific gait deviations in pediatric patients with X-linked hypophosphatemia. Gait Posture. 2020;81:78\u201384.","journal-title":"Gait Posture"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04267-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04267-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04267-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:03:37Z","timestamp":1781636617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04267-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4267"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04267-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest regarding this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}